About this event
The critical importance of PROs for Emerging Biopharma Companies
In today’s competitive landscape, biotech and emerging biopharma companies (EBPs) must demonstrate the value of their innovations early and convincingly. Electronic Clinical Outcome Assessments (eCOA), including Patient Reported Outcomes (PROs), have become a strategic asset in this effort.
In this webinar, Adeline Meilhoc, Clinical Psychologist – Biotech, Pharma & CRO clinical research specialist and strategic advisor, and Estelle Haenel, Chief Medical Officer @Kayentis, will explore how eCOA and ePRO data will enhance the clinical, scientific, and methodological rigor of your trial. They will address their benefit for key opinion leaders and patient associations engagement.
Ultimately, they will demonstrate that, beyond clinical insights, PROs also contribute to company valuation and market access strategies, meeting regulatory expectations, supporting early-phase development, and offering a compelling return on investment.
Key topics
- ePRO, eCOA… understanding the basics
- ePRO to demonstrate the therapeutic value of your molecule
- ePRO to accelerate market access, and enrich cost-effectiveness analyses
- ePRO to convince investors during the fundraising process
Hosted by
-
Team member
Estelle HaenelT
Joined Kayentis as Chief Medical Officer in 2019. Estelle drives the scientific strategy of the company, collaborating with the scientific advisory board and focusing on patient and site engagement. She has 25+ years of experience in pre-clinical and clinical research in Top 5 Pharma and Biotech companies. A Doctor of Pharmacy, Estelle also has a Masters in Endocrinology and Cellular Interaction and a PhD in Biochemistry and Molecular Biology.
-
Guest speaker
Adeline Meilhoc Clinical Psychologist – Biotech, Pharma & CRO clinical research specialistG
Has built a distinguished career in clinical therapeutics development, holding key roles at UCB Pharma, Parexel Inc., Cegedim Strategic Data, and Acticor Biotech. She has led departments in clinical trial feasibility, study start-up, medical imaging, and commercial development, serving as VP Medical Affairs and Clinical Operations, Head of Global Clinical Development, and VP Business Development. Specializing in business strategy, she has developed innovative Marketing & Sales strategies for eClinical tools and Patient-Reported Outcomes (PROs), supporting healthcare professionals and medical device companies while managing her own ventures. Her expertise in Real World Evidence and market access operations gives her a comprehensive view of drug development and successful product launches.
Kayentis
Embark on a seamless eCOA clinical trial experienceKayentis, a global leader in eCOA and Decentralized Clinical Trial solutions, empowers pharma, biotech, and CROs to streamline data collection in clinical trials, enhancing simplicity, efficiency, and data quality.
